Smith & Wesson Brands, Inc. (SWBI)

Smith & Wesson pairs a conservative balance sheet and strong free cash flow (~14% FCF yield, ~0.8x net debt/EBITDA, Altman Z 5.07) with a clear demand recovery (FY2026 revenue +10.4%, Q1 FY2027 +32.3% and a swing to profit) — but GAAP margins remain thin, litigation exposure is heavy, the 5-year growth CAGRs are deeply negative, and the DCF models point below the market price. A mixed but defensible fundamental profile: real cash-generation and recovery momentum offset by cyclical, legal, and regulatory uncertainty.

Dominant catalyst is the 2026-09-03 Q1 FY2027 earnings beat (announced confidence): revenue up 32.3% with a $0.06 EPS swing versus a consensus loss drove a ~12% after-hours pop, but the print is eight days trailing and only partially digested, and the media delta cooled from a +0.38 baseline to +0.15 in-window rather than inflecting higher. Red-Flag Screen is clean and no forward-dated catalyst exists, so the read is a constructive mixed/forming setup held below the top band by the rewarded-but-trailing catalyst ceiling.

Early-stage reversal breakout. Price 13.64 reclaimed the SMA20 (13.17), EMA9/21 (13.26/13.36), WMA/DEMA cluster and the SMA200 (13.41) on a two-day +5% rally with clear volume expansion (1.19M shares on 09-18 vs 400-600K in the prior sessions). RSI14 53.16 has risen from 41 on 09-16 and the MACD histogram is positive (+0.11) and expanding for eight straight sessions while the line (-0.21) is still converging on the signal (-0.32). Weaknesses: price remains below the SMA50 (14.06), the MACD line is still below zero, and ADX14 at 16.01 shows the trend is young - the profile of a fresh reversal rather than an established uptrend, which is why the entry is a breakout buy stop above Friday's high rather than a limit bid into the dip. Score 4.